Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): Lack of utility to stratify cancer risks associated with HGPIN

Huiying He, Adeboye O. Osunkoya, Paula Carver, Sara Falzarano, Eric Klein, Cristina Magi-Galluzzi, Ming Zhou

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

OBJECTIVES • To evaluate how often ERG, a highly prostate-cancer- specific marker, is expressed in isolated high grade prostatic intraepithelial neoplasia (HGPIN) by immunohistochemistry. • To study whether a positive ERG immunostain in HGPIN correlates with prostate cancer (PCa) detection in subsequent repeat biopsies. PATIENTS AND METHODS • Patients with initial HGPIN in biopsies and at least one follow-up prostate biopsy were included. • Biopsies with HGPIN were immunostained for ERG. • The ERG staining results were then correlated with the PCa risk in subsequent biopsies. RESULTS • The mean age of 94 patients was 63 years (range 48-78). A mean of 1.8 (range 1-5) repeat biopsy sessions were carried out at a mean interval of 27.4 months (range 1.5-140). The repeat biopsies showed PCa and non-cancer lesions (benign, HGPIN, atypical glands suspicious for cancer) in 36 patients (38%) and 58 patients (62%) respectively. • ERG immunostain was positive in five (5.3%) biopsies with HGPIN, in which PCa was found in two (40%) subsequent biopsies. Of 89 biopsies with negative ERG staining, PCa was found in 34 (38%) repeat biopsies. The cancer detection rate was not different between ERG positive and negative cases (P = 0.299). CONCLUSIONS • This is the first study to investigate the ERG protein expression in prostate biopsy containing HGPIN only and its use to stratify the cancer risk associated with HGPIN. We found that ERG expression is distinctly uncommon in isolated HGPIN (5.3%). • Positive ERG expression is not associated with increased cancer detection in subsequent repeat biopsies. The use of ERG immunostain in the evaluation and cancer risk stratification of HGPIN is of limited value.

Original languageEnglish (US)
JournalBJU International
Volume110
Issue number11 B
DOIs
StatePublished - Dec 1 2012

Fingerprint

Prostatic Intraepithelial Neoplasia
Prostatic Neoplasms
Biopsy
Neoplasms
Proteins
Prostate
Negative Staining

Keywords

  • ERG
  • High grade PIN
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN) : Lack of utility to stratify cancer risks associated with HGPIN. / He, Huiying; Osunkoya, Adeboye O.; Carver, Paula; Falzarano, Sara; Klein, Eric; Magi-Galluzzi, Cristina; Zhou, Ming.

In: BJU International, Vol. 110, No. 11 B, 01.12.2012.

Research output: Contribution to journalArticle

He, Huiying ; Osunkoya, Adeboye O. ; Carver, Paula ; Falzarano, Sara ; Klein, Eric ; Magi-Galluzzi, Cristina ; Zhou, Ming. / Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN) : Lack of utility to stratify cancer risks associated with HGPIN. In: BJU International. 2012 ; Vol. 110, No. 11 B.
@article{c6632acb5a8b4b529bbeed36a131a583,
title = "Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): Lack of utility to stratify cancer risks associated with HGPIN",
abstract = "OBJECTIVES • To evaluate how often ERG, a highly prostate-cancer- specific marker, is expressed in isolated high grade prostatic intraepithelial neoplasia (HGPIN) by immunohistochemistry. • To study whether a positive ERG immunostain in HGPIN correlates with prostate cancer (PCa) detection in subsequent repeat biopsies. PATIENTS AND METHODS • Patients with initial HGPIN in biopsies and at least one follow-up prostate biopsy were included. • Biopsies with HGPIN were immunostained for ERG. • The ERG staining results were then correlated with the PCa risk in subsequent biopsies. RESULTS • The mean age of 94 patients was 63 years (range 48-78). A mean of 1.8 (range 1-5) repeat biopsy sessions were carried out at a mean interval of 27.4 months (range 1.5-140). The repeat biopsies showed PCa and non-cancer lesions (benign, HGPIN, atypical glands suspicious for cancer) in 36 patients (38{\%}) and 58 patients (62{\%}) respectively. • ERG immunostain was positive in five (5.3{\%}) biopsies with HGPIN, in which PCa was found in two (40{\%}) subsequent biopsies. Of 89 biopsies with negative ERG staining, PCa was found in 34 (38{\%}) repeat biopsies. The cancer detection rate was not different between ERG positive and negative cases (P = 0.299). CONCLUSIONS • This is the first study to investigate the ERG protein expression in prostate biopsy containing HGPIN only and its use to stratify the cancer risk associated with HGPIN. We found that ERG expression is distinctly uncommon in isolated HGPIN (5.3{\%}). • Positive ERG expression is not associated with increased cancer detection in subsequent repeat biopsies. The use of ERG immunostain in the evaluation and cancer risk stratification of HGPIN is of limited value.",
keywords = "ERG, High grade PIN, Prostate cancer",
author = "Huiying He and Osunkoya, {Adeboye O.} and Paula Carver and Sara Falzarano and Eric Klein and Cristina Magi-Galluzzi and Ming Zhou",
year = "2012",
month = "12",
day = "1",
doi = "10.1111/j.1464-410X.2012.11557.x",
language = "English (US)",
volume = "110",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "11 B",

}

TY - JOUR

T1 - Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN)

T2 - Lack of utility to stratify cancer risks associated with HGPIN

AU - He, Huiying

AU - Osunkoya, Adeboye O.

AU - Carver, Paula

AU - Falzarano, Sara

AU - Klein, Eric

AU - Magi-Galluzzi, Cristina

AU - Zhou, Ming

PY - 2012/12/1

Y1 - 2012/12/1

N2 - OBJECTIVES • To evaluate how often ERG, a highly prostate-cancer- specific marker, is expressed in isolated high grade prostatic intraepithelial neoplasia (HGPIN) by immunohistochemistry. • To study whether a positive ERG immunostain in HGPIN correlates with prostate cancer (PCa) detection in subsequent repeat biopsies. PATIENTS AND METHODS • Patients with initial HGPIN in biopsies and at least one follow-up prostate biopsy were included. • Biopsies with HGPIN were immunostained for ERG. • The ERG staining results were then correlated with the PCa risk in subsequent biopsies. RESULTS • The mean age of 94 patients was 63 years (range 48-78). A mean of 1.8 (range 1-5) repeat biopsy sessions were carried out at a mean interval of 27.4 months (range 1.5-140). The repeat biopsies showed PCa and non-cancer lesions (benign, HGPIN, atypical glands suspicious for cancer) in 36 patients (38%) and 58 patients (62%) respectively. • ERG immunostain was positive in five (5.3%) biopsies with HGPIN, in which PCa was found in two (40%) subsequent biopsies. Of 89 biopsies with negative ERG staining, PCa was found in 34 (38%) repeat biopsies. The cancer detection rate was not different between ERG positive and negative cases (P = 0.299). CONCLUSIONS • This is the first study to investigate the ERG protein expression in prostate biopsy containing HGPIN only and its use to stratify the cancer risk associated with HGPIN. We found that ERG expression is distinctly uncommon in isolated HGPIN (5.3%). • Positive ERG expression is not associated with increased cancer detection in subsequent repeat biopsies. The use of ERG immunostain in the evaluation and cancer risk stratification of HGPIN is of limited value.

AB - OBJECTIVES • To evaluate how often ERG, a highly prostate-cancer- specific marker, is expressed in isolated high grade prostatic intraepithelial neoplasia (HGPIN) by immunohistochemistry. • To study whether a positive ERG immunostain in HGPIN correlates with prostate cancer (PCa) detection in subsequent repeat biopsies. PATIENTS AND METHODS • Patients with initial HGPIN in biopsies and at least one follow-up prostate biopsy were included. • Biopsies with HGPIN were immunostained for ERG. • The ERG staining results were then correlated with the PCa risk in subsequent biopsies. RESULTS • The mean age of 94 patients was 63 years (range 48-78). A mean of 1.8 (range 1-5) repeat biopsy sessions were carried out at a mean interval of 27.4 months (range 1.5-140). The repeat biopsies showed PCa and non-cancer lesions (benign, HGPIN, atypical glands suspicious for cancer) in 36 patients (38%) and 58 patients (62%) respectively. • ERG immunostain was positive in five (5.3%) biopsies with HGPIN, in which PCa was found in two (40%) subsequent biopsies. Of 89 biopsies with negative ERG staining, PCa was found in 34 (38%) repeat biopsies. The cancer detection rate was not different between ERG positive and negative cases (P = 0.299). CONCLUSIONS • This is the first study to investigate the ERG protein expression in prostate biopsy containing HGPIN only and its use to stratify the cancer risk associated with HGPIN. We found that ERG expression is distinctly uncommon in isolated HGPIN (5.3%). • Positive ERG expression is not associated with increased cancer detection in subsequent repeat biopsies. The use of ERG immunostain in the evaluation and cancer risk stratification of HGPIN is of limited value.

KW - ERG

KW - High grade PIN

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84876452523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876452523&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2012.11557.x

DO - 10.1111/j.1464-410X.2012.11557.x

M3 - Article

C2 - 23046279

AN - SCOPUS:84876452523

VL - 110

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 11 B

ER -